| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Ronald G Hall | |
| Sara D Brouse | |||
| Kathleen A Hazlewood | |||
| William D Pitcher | |||
| P2860 | cites work | Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. | Q53338170 |
| Epidemiological Profile of Linezolid‐Resistant Coagulase‐Negative Staphylococci | Q59230736 | ||
| Renal pathological findings in infective endocarditis | Q73173544 | ||
| Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals | Q80044011 | ||
| A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia | Q80783502 | ||
| Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 | ||
| Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981 | Q24671879 | ||
| Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine | Q30699440 | ||
| Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study | Q31918107 | ||
| Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence | Q33371390 | ||
| Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections | Q33836490 | ||
| The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 | ||
| Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y | Q34426508 | ||
| Vancomycin: a history | Q34472263 | ||
| Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer | Q34489730 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study | Q34900607 | ||
| Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists | Q34910366 | ||
| Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity | Q36538707 | ||
| Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. | Q36735202 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Multicenter evaluation of vancomycin dosing: emphasis on obesity. | Q36961341 | ||
| Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates | Q37089738 | ||
| Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus | Q38387768 | ||
| Acute kidney injury, mortality, length of stay, and costs in hospitalized patients | Q39730814 | ||
| Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin | Q42042890 | ||
| Mild nephrotoxicity associated with vancomycin use. | Q42198840 | ||
| A prospective study of adverse reactions associated with vancomycin therapy | Q42226234 | ||
| Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia | Q43781411 | ||
| Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections | Q43996924 | ||
| Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? | Q44379429 | ||
| Targeting Superoxide Dismutase to Renal Proximal Tubule Cells Attenuates Vancomycin-induced Nephrotoxicity in Rats | Q44441468 | ||
| Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin | Q44721295 | ||
| Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells | Q45090976 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam | Q46634329 | ||
| Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity | Q46762962 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vancomycin | Q424027 |
| assassination | Q3882219 | ||
| character assassination | Q63241849 | ||
| P304 | page(s) | 182.e1-7 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? | |
| P478 | volume | 123 |
| Q55496455 | A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated stud |
| Q34751913 | Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children |
| Q46698824 | Acute kidney injury during vancomycin therapy in critically ill children |
| Q38285837 | Acute kidney injury induced by antimicrobial agents in the elderly: awareness and mitigation strategies |
| Q49921680 | Adverse effects of intravenous vancomycin-based prophylaxis during therapy for pediatric acute myeloid leukemia |
| Q35065894 | Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients |
| Q64240085 | Assessment of vancomycin utilization among Lebanese hospitals |
| Q38185097 | Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections |
| Q38111809 | Clinical use of biomarkers for toxicant-induced acute kidney injury |
| Q40176015 | Conventional- versus high-dose vancomycin regimen in patients with acute bacterial meningitis: a randomized clinical trial. |
| Q37809059 | Current medical management of diabetic foot infections |
| Q44770615 | Development of acute kidney injury during continuous infusion of vancomycin in septic patients. |
| Q41206165 | Does Combination Therapy With Vancomycin and Piperacillin-Tazobactam Increase the Risk of Nephrotoxicity Versus Vancomycin Alone in Pediatric Patients? |
| Q38907793 | Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options). |
| Q41500288 | Efficacy of Plectranthus amboinicus (Lour.) Spreng in a Murine Model of Methicillin-Resistant Staphylococcus aureus Skin Abscesses |
| Q36799447 | Emergency Department vancomycin use: dosing practices and associated outcomes |
| Q40091038 | Enigma: infection or allergy? Vancomycin-induced DRESS syndrome with dialysis-dependent renal failure and cardiac arrest. |
| Q89204650 | Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates |
| Q57216392 | Evaluation of risk factors for vancomycin-induced nephrotoxicity |
| Q42385439 | Evaluation of the Safety of a Vancomycin Nomogram Used to Achieve Target Trough Concentrations |
| Q54232841 | Evaluation of vancomycin therapy in the adult ICUs of a teaching hospital in southern Iran. |
| Q39127162 | Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy. |
| Q36439072 | In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. |
| Q52673578 | Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia. |
| Q37763155 | Nanoscale particle therapies for wounds and ulcers |
| Q37612957 | Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime |
| Q49683582 | Novel approach to vancomycin level monitoring: Impact of a multidisciplinary monitoring system on timing of vancomycin levels |
| Q35862844 | Optimization of time to initial vancomycin target trough improves clinical outcomes |
| Q93061563 | Optimizing Vancomycin Dosing in Chronic Kidney Disease by Deriving and Implementing a Web-Based Tool Using a Population Pharmacokinetics Analysis |
| Q38164668 | Performance of a divided-load intravenous vancomycin dosing strategy for critically ill patients. |
| Q37960131 | Pharmacokinetic drug-drug interactions with methotrexate in oncology |
| Q38066654 | Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia |
| Q42772417 | Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model |
| Q30569251 | Prevention of vancomycin induced nephrotoxicity: a review of preclinical data |
| Q36173007 | Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity |
| Q33429168 | Safety profiles of old and new antimicrobials for the treatment of MRSA infections. |
| Q35942538 | Simultaneous and Direct Determination of Vancomycin and Cephalexin in Human Plasma by Using HPLC-DAD Coupled with Second-Order Calibration Algorithms |
| Q38061039 | Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter |
| Q37840723 | Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults |
| Q38687487 | The Nephrotoxicity of Vancomycin |
| Q38103768 | Therapeutic drug monitoring for tomorrow. |
| Q34494676 | Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients |
| Q30278491 | Top Guns: The "Maverick" and "Goose" of Empiric Therapy |
| Q92494869 | Utilizing the Patient Care Process to Minimize the Risk of Vancomycin-Associated Nephrotoxicity |
| Q30409849 | Vancomycin and nephrotoxicity: just another myth? |
| Q38964588 | Vancomycin blocks autophagy and induces interleukin-1β release in macrophages |
| Q37892556 | Vancomycin dosing and monitoring 2 years after the guidelines |
| Q54891594 | Vancomycin in the Kidney-A Novel Cast Nephropathy. |
| Q38255364 | Vancomycin nephrotoxicity: a review |
| Q38258649 | Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. |
| Q30278775 | Vancomycin-Associated Nephrotoxicity: The Obesity Factor |
| Q33585827 | Vancomycin-associated acute kidney injury: A cross-sectional study from a single center in China. |
| Q37992997 | Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review |
Search more.